Faeth Therapeutics' CFO Has Deployed $727,000 in Personal Capital Over Two Weeks
Faeth Therapeutics CFO Brian Stephenson deployed $326K in personal trust capital across four tranches June 29βJuly 1, extending a $727K multi-week accumulation campaign. 46,688 shares total. No plan.
π’ Insider Activity Score: 84/100
Brian C. Stephenson, CFO of Faeth Therapeutics, filed a Form 4 on July 1, 2026 disclosing the purchase of 13,634 common shares through the Brian Stephenson Revocable Trust across four tranches spanning June 29 through July 1 at prices ranging from $22.95 to $24.98 for approximately $326,127 in personal trust capital β extending a multi-week accumulation campaign that began with a parallel purchase on June 24-26, combining for approximately $727,000 deployed across 46,688 shares in the trust. No 10b5-1 plan governs either campaign. The revocable trust structure confirms personal capital. The two-week sustained buying pattern at an oncology-stage biotech entering active clinical testing is the specific signal this series documents as meaningful.
The Two-Week Campaign: Sustained Personal Conviction
The June 24-26 opening campaign and the June 29 through July 1 continuation β two separate multi-day accumulation events within a fourteen-day window β confirm a CFO who has been repeatedly deploying personal trust capital at every available opportunity across the two-week period.
This series documented the same behavioral pattern in the Hallador Energy new director analysis: multiple separate purchase events within days of each other, no plan governing any of them, personal capital in each case. A CFO making independent decisions to buy on four separate tranches across three days β following a prior multi-day campaign two weeks earlier β is not executing a single sign-on purchase or a routine compensation equity event. He is making repeated, independent, discretionary judgments that the current price represents a compelling personal financial entry.
The $22.95 to $24.98 Ascending Corridor
The four-tranche execution across a $22.95 floor to $24.98 peak reflects the CFO continuing to buy as the price appreciated across the three-day window β the opposite of the downward execution gradient, but analytically consistent with sustained conviction: a buyer who accepts a higher price on successive sessions has not been deterred by the rising cost of accumulation.
The ascending corridor combined with the prior campaign's pricing establishes the specific demand zone Stephenson has been defending β personal trust capital absorbing available supply at whatever price the micro-cap oncology biotech's market offered across each session.
The Revocable Trust Vehicle: Personal Estate Capital
The Brian Stephenson Revocable Trust is the personal estate planning vehicle through which the CFO manages his Faeth Therapeutics equity accumulation β the same revocable trust structure this series has documented across the Lululemon Bergh family trust purchase, the Roku Wood 2017 Trust, and the Strategy CEO Phong Le Revocable Trust.
A CFO deploying revocable trust capital β the personal and estate financial resources of his household β into a clinical-stage oncology biotech across multiple separate sessions is making the most personally committed version of the conviction buy available: estate capital, no plan, repeated decisions, and a pipeline entering the clinical testing phase that will determine the company's commercial trajectory.
The Oncology Pipeline Context
Faeth Therapeutics develops precision oncology therapies at the intersection of cancer metabolism and dietary intervention β a clinical-stage approach targeting the specific metabolic vulnerabilities that cancer cells exploit, combining therapeutic agents with dietary protocols designed to deprive tumors of the nutrients their metabolic dependencies require.
The pipeline entering active clinical testing milestones is the specific binary event horizon that makes a CFO's sustained personal trust accumulation analytically significant: the clinical data that active testing generates will determine whether the metabolic oncology thesis delivers the outcomes the $727,000 in personal trust capital is betting on.
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage precision oncology company developing therapies that target cancer cell metabolic vulnerabilities through combined therapeutic and dietary intervention protocols. CFO Brian Stephenson's Brian Stephenson Revocable Trust holds 46,688 common shares following the completion of the two-week $727,000 personal capital accumulation campaign. Faeth Therapeutics trades on the Nasdaq under the ticker FTH.
How to Think About This
Stephenson's two-week campaign scores 84/100 β a clinical-stage oncology CFO deploying $727,000 in personal revocable trust capital across two separate multi-day accumulation events without a pre-arranged plan, as the pipeline enters active clinical testing.
The sustained two-week pattern is the signal amplifier. A single $326,000 purchase would score lower. Two campaigns in fourteen days β no plan, personal trust capital, multiple independent sessions β is the CFO expressing repeated conviction at every available opportunity across the specific clinical window that will determine whether the metabolic oncology thesis delivers.
The first campaign established the position. The second extended it. The clinical testing will test both.